Moxilubant
Moxilubant (CGS-25019C; LTB-019) is an orally active BLT1 antagonist which inhibits LTB4 signaling with a potency of 2–4 nM. Moxilubant can be used for cancer research[1].
Product Specifications
CAS Number
[146978-48-5]
Product Name Alternative
CGS 25019C (free base)
UNSPSC
12352005
Target
Leukotriene Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/moxilubant.html
Purity
99.83
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
CC(C)N(C(C)C)C(C1=CC(OC)=C(OCCCCCOC2=CC=C(C(N)=N)C=C2)C=C1)=O
Molecular Formula
C26H37N3O4
Molecular Weight
455.59
References & Citations
[1]Bhatt L, et al. Recent advances in clinical development of leukotriene B4 pathway drugs. Semin Immunol. 2017 Oct;33:65-73.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
